Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2025)

Lyell Immunopharma's Asset Utilization Ratio history spans 5 years, with the latest figure at 0.0 for Q3 2025.

  • For Q3 2025, Asset Utilization Ratio rose 4.45% year-over-year to 0.0; the TTM value through Sep 2025 reached 0.0, up 4.45%, while the annual FY2024 figure was 0.0, 36.19% down from the prior year.
  • Asset Utilization Ratio for Q3 2025 was 0.0 at Lyell Immunopharma, down from 0.0 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.09 in Q1 2023 and bottomed at 0.0 in Q2 2024.
  • The 5-year median for Asset Utilization Ratio is 0.01 (2022), against an average of 0.02.
  • The largest annual shift saw Asset Utilization Ratio skyrocketed 1063.08% in 2023 before it plummeted 99.9% in 2024.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.01 in 2021, then surged by 865.78% to 0.09 in 2022, then crashed by 99.81% to 0.0 in 2023, then crashed by 34.69% to 0.0 in 2024, then fell by 5.96% to 0.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Asset Utilization Ratio are 0.0 (Q3 2025), 0.0 (Q2 2025), and 0.0 (Q1 2025).